Induction and activation of the Akt signalling pathway, along with the presence of gain of function mutations, are observed in a wide number of cancers including thyroid, breast, colon and pancreatic cancers [104] and as such aberrant Akt signalling is highly oncogenic [105,106]. This evidence concerns the gene AKT1 and pancreatic neoplasm.